CD274 and non-small cell lung carcinoma: The standard of care treatment for patients with stage IV NSCLC and PD-L1 TPS ≥50% has evolved from platinum-based chemotherapy to pembrolizumab monotherapy 200 mg every 3 weeks (Q3W) due to the results found in KEYNOTE-024 [7].